Diabetes is a common age-dependent complication of cystic fibrosis (CF) that is strongly influenced by modifier genes. We conducted a genome-wide association study in 3,059 individuals with CF (644 with CF-related diabetes [CFRD]) and identified single nucleotide polymorphisms (SNPs) within and 5′ to the
SLC26A9 gene that associated with CFRD (hazard ratio [HR] 1.38;
P = 3.6 × 10
−8). Replication was demonstrated in 694 individuals (124 with CFRD) (HR, 1.47;
P = 0.007), with combined analysis significant at
P = 9.8 × 10
−10. SLC26A9 is an epithelial chloride/bicarbonate channel that can interact with the CF transmembrane regulator (CFTR), the protein mutated in CF. We also hypothesized that common SNPs associated with type 2 diabetes also might affect risk for CFRD. A previous association of CFRD with SNPs in
TCF7L2 was replicated in this study (
P = 0.004; combined analysis
P = 3.8 × 10
−6), and type 2 diabetes SNPs at or near
CDKAL1,
CDKN2A/B, and
IGF2BP2 were associated with CFRD (
P < 0.004). These five loci accounted for 8.3% of the phenotypic variance in CFRD onset and had a combined population-attributable risk of 68%. Diabetes is a highly prevalent complication of CF, for which susceptibility is determined in part by variants at
SLC26A9 (which mediates processes proximate to the CF disease-causing gene) and at four susceptibility loci for type 2 diabetes in the general population.Cystic fibrosis (CF) is a common life-limiting monogenic disease in Caucasians caused by defects in an epithelial chloride channel, CF transmembrane regulator (CFTR), which is expressed across tissues, including sweat glands, pancreas, and lung. Diabetes is an age-dependent complication of CF that affects 19% of adolescents and 40–50% of adults with CF (
1). CF-related diabetes (CFRD) is associated with worse lung disease, malnutrition, and mortality (
2), and treating CFRD substantially improves outcomes (
1,
3). Risk factors for CFRD include pancreatic exocrine insufficiency (
4), female sex (
5), and liver disease (
6). Genetic modifiers (genes other than
CFTR) contribute to the risk of CFRD (
7), and identification of these modifiers could give insight into the pathophysiology of CFRD.The clinical and histologic features of CFRD share some similarities with other forms of diabetes in the general population, but there are also distinct differences. For example, type 2 diabetes and CFRD are associated with a subacute decline in β-cell function and production of islet amyloid (
8,
9). In contrast, insulin sensitivity is reduced in type 2 diabetes but is generally normal in CFRD (except during exacerbations or glucocorticoid treatment) (
1). These findings suggest that CFRD and type 2 diabetes have both common and distinct mechanisms; therefore, dissection of the contributing pathways could be informative for both conditions.Identification of genes that confer risk for CFRD can address the degree of overlap with type 2 diabetes. There is a reasonable basis for a genetic approach as follows: >50 common gene variants associate with type 2 diabetes (
10); a family history of type 2 diabetes (i.e., diabetes in non-CF family members) approximately triples the risk for CFRD (
11); and in a total of 1,745 CF individuals, we previously demonstrated that
TCF7L2, a susceptibility gene for type 2 diabetes, confers risk for CFRD (
11). The formation of the CF Genetic Modifier Consortium and genome-wide single nucleotide polymorphism (SNP) typing of ∼3,500 CF patients (
12) afforded an opportunity to search for unique and shared risk factors using genome-wide association analysis. To increase the power for detecting variants affecting both CFRD and type 2 diabetes, we also tested candidate type 2 diabetes SNPs at 7 loci for association with CFRD.
相似文献